GURUFOCUS.COM » STOCK LIST » USA » NYSE » ResMed Inc (NYSE:RMD) » Definitions » GF Value
Switch to:

ResMed (NYSE:RMD) GF Value

: $278.61 (As of Today)
View and export this data going back to 1995. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-02-26), ResMed's share price is $183.29. ResMed's GF Value is $278.61. Therefore, ResMed's Price-to-GF-Value for today is 0.66.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes ResMed is Significantly Undervalued.


ResMed  (NYSE:RMD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

ResMed's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=183.29/278.61
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ResMed GF Value Related Terms

Thank you for viewing the detailed overview of ResMed's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (NYSE:RMD) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123